Reviewing Global Blood Therapeutics Inc. (GBT)’s and CTI BioPharma Corp. (NASDAQ:CTIC)’s results

Global Blood Therapeutics Inc. (NASDAQ:GBT) and CTI BioPharma Corp. (NASDAQ:CTIC), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Global Blood Therapeutics Inc. N/A 0.00 174.19M -3.42 0.00
CTI BioPharma Corp. 26.29M 2.08 29.40M -0.87 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Global Blood Therapeutics Inc. and CTI BioPharma Corp.


Table 2 provides us Global Blood Therapeutics Inc. and CTI BioPharma Corp.?s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Global Blood Therapeutics Inc. 0.00% -33.1% -30.7%
CTI BioPharma Corp. -111.83% -77.4% -49.1%

Risk & Volatility

Global Blood Therapeutics Inc. is 113.00% more volatile than Standard and Poor’s 500 because the stock has a beta of 2.13. CTI BioPharma Corp. on the other hand, has 1.59 beta which makes it 59.00% more volatile compared to Standard and Poor’s 500.


Global Blood Therapeutics Inc. has a Current Ratio of 14.6 and a Quick Ratio of 14.6. Competitively, CTI BioPharma Corp.’s Current Ratio is 3.6 and has 3.6 Quick Ratio. Global Blood Therapeutics Inc.’s better ability to pay short and long-term obligations than CTI BioPharma Corp.

Analyst Recommendations

Global Blood Therapeutics Inc. and CTI BioPharma Corp. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Global Blood Therapeutics Inc. 0 1 1 2.50
CTI BioPharma Corp. 0 0 0 0.00

$76 is Global Blood Therapeutics Inc.?s consensus price target while its potential upside is 50.58%.

Insider & Institutional Ownership

Institutional investors owned 13.28% of Global Blood Therapeutics Inc. shares and 61.1% of CTI BioPharma Corp. shares. Insiders owned roughly 2.4% of Global Blood Therapeutics Inc.’s shares. Competitively, insiders own roughly 0.1% of CTI BioPharma Corp.?s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Global Blood Therapeutics Inc. 0.21% 10.19% 60.95% 8.73% -10.22% 28.6%
CTI BioPharma Corp. 21.23% 0% -30.41% -36.02% -70.32% 62.21%

For the past year Global Blood Therapeutics Inc. was less bullish than CTI BioPharma Corp.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.